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Abstract
A hallmark of the tumor microenvironment in malignant tumor is extracellular acidosis, which can
be exploited for targeted delivery of drugs and imaging agents. A pH sensitive paramagnetic
nanoaparticle (NP) is developed by incorporating GdDOTA-4AmP MRI contrast agent and pHLIP
(pH Low Insertion Peptide) into the surface of a G5–PAMAM dendrimer. pHLIP showed pHselective insertion and folding into cell membranes, but only in acidic conditions. We
demonstrated that pHLIP-conjugated Gd44-G5 paramagnetic nanoparticle binds and fuses with
cellular membrane at low pH, but not at normal physiological pH, and that it promotes cellular
uptake. Intracellular trafficking of NPs showed endosomal/lysosomal path ways.
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Overexpressed receptors and enzymes in cancer cells have received primary consideration as
biomarkers for targeted imaging and/or therapy.1 The variability of the cells in many human
cancers, however, may limit approaches based on targeting specific cancer cell receptors.2
Recent gene expression studies in cancer cells have demonstrated that many molecules,
including various receptors are up- or down-regulated in individual tumor cells, resulting
heterogeneous cell surfaces.3 Therefore, progress for therapeutic tumor targeting is
hampered by the diverse and heterogeneous nature of cancer, and relying on any single
tumor biomarker for even one type of cancer can be problematic.
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Recently, new targeting strategies have emerged as a way of improving the targeting
efficiency of nanocarriers. These strategies utilize the unique microenvironment4–6 of tumor
cells, i.e. “tumoral extracellular environment,” as a molecular cue for activating longcirculating nanocarriers to release the drug or facilitate their cellular uptake upon arrival at
the targeted tumor sites. These considerations lead to physiological markers of tumors as a
focus for both detection and treatment.5,6,7
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The tumor microenvironment is frequently characterized by an acidic extracellular pHe and a
neutral-to-alkaline intracellular pHi.8–10 This kind of pH gradient is not observed in normal
tissues and blood.11 An acidic tumor pHe is caused by an increase glycolysis in tumor cells,
which generates increased extracellular levels of bi-carbonate under aerobic conditions,12,13
or lactic acid under anaerobic conditions.14–16 Poor perfusion and reduced passive buffering
capacity in the extracellular tumor microenvironment further exacerbates the decrease in
tumor pHe.17,18 To better understand the mechanism of cellular internalization of
nanoparticles at different pH values with dissipative particle dynamics simulations pHresponsive nano-sized drug delivery system that incorporated pH-sensitive polymers has
recently been developed.11,19
Recently, selective targeting of acidic cancer cells without affecting normal cells has been
demonstrated.20,21 This method is based on application of a water-soluble membrane
peptide PHLIP-pH Low Insertion Peptide, which acts as a nanosyringe. Acidic pH (<7.0)
promotes the protonation of one or two aspartic residues in this peptide and it triggers the
insertion of the pHLIP into the cell membrane, as well as the formation of a transmembrane
alpha helix.22 At neutral pH, the pHLIP peptide binds only weakly to the surface of the cell
membrane, without insertion of the peptide.23 pH-selective insertion and folding within
membranes has been demonstrated to occur only in acidic tissues in vivo,24,25 including in
solid tumors (human and mouse).26,27 Once inserted across the cell membranes within the
acidic tissue, pHLIP remains in this state for a long period of time.21,26 The affinity of the
peptide for a lipid bilayer is about 20 times higher at acidic pHs (<7.0) than at higher pHs.28
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It has been demonstrated in mice that the N-terminus of pHLIP when conjugated with
various fluorescent probes or a 64Cu-DOTA chelate that is used for PET imaging, can
identify tumor sites and accumulate in tumor tissues of various types and at various stages of
tumor development.21,26 Ability of pHLIP to target tumors correlates with the
aggressiveness of tumors: highly metastatic tumors, which are known to be more acidic29
than non-metastatic ones are targeted much better by fluorescent pHLIP.30 However, the
shallow depth of tissue light penetration limits the use to endoscopy and optical imaging in

ACS Sens. Author manuscript; available in PMC 2017 January 05.

Janic et al.

Page 3

Author Manuscript

skin cancers. On the other hand, nuclear medicine techniques (such as PET or SPECT),
although sensitive, are limited in their use due to lack of spatial resolution with respect to
anatomical landmarks, and the short half-life of usable radioisotopes.
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Magnetic resonance imaging (MRI) is a non-invasive and non-ionizing method that provides
high spatial image resolution throughout the tissue. In addition, MRI method has no tissue
penetration problem. Although there are many reports on pHLIP-tagged fluorescent and
radiotracer imaging probes, no pHLIP-conjugated MRI probes have been reported. We have
recently developed dendrimer-based pH-responsive MRI nanoprobe.31,32 This paramagnetic
nanoparticle is an attractive foundation for the development of a broadly useful, “smart”
nanoparticle platform for both targeted acidic tumor imaging and drug delivery. This
platform might easily accommodate targeting ligands for selective localization at the acidic
tumor microenvironment as well as the therapeutic drugs that can be released selectively into
tumor cells. Therefore, we investigated the pHLIP-tagged dendrimer-based pH-responsive
paramagnetic nanoparticles in targeting cancer cells based on a physiological characteristic
of tumor microenvironment. To monitor intracellular internalization and trafficking of
paramagnetic nanoparticle, we also conjugated the fluorescent dye to the nanostructure.
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We have synthesized a pH-responsive paramagnetic nanoparticle using our previously
published synthetic methods.32 The particle corresponds to a G5-dendrimer with an average
of 44 chelated GdDOTA-4AmP5- ions per dendrimer. In this report, Gd44-G5 dendrimer was
reacted with a heterobifunctional cross-linker, sulfosuccinimidyl 6-(3'-[2-pyridyldithio]propionamido)hexanoate (sulfo-LC-SPDP) and then pyridinyldisulfide activated Gd44-G5
dendrimer was coupled with a C-terminus cysteine group of biotinylated Bt-pHLIP
(AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG-dpeg4Biotin) (New England
Peptide, Gardner, MA, USA) to form a disulfide bond. The conjugate was purified by
diafiltration (C-10) to produce a final conjugate, Gd44-G5-ss-Bt-pHLIP (Figure 1). A biotin
molecule was attached to the C-terminus of pHLIP in order to quantify the number of pHLIP
peptides conjugated with Gd44-G5. The number of biotin molecules conjugated with
PAMAM Gd44-G5 dendrimer was determined using HABA-avidin assay (Pierce Chemical).
The HABA assay with biotin and avidin revealed that on average 3.1 molecules of biotin
were present in the Gd44-G5-ss-Bt-pHLIP dendrimer. Since biotin was attached to the
pHLIP peptide, an average of, 3.1 pHLIP peptides were also present in a Gd44-G5-ss-BtpHLIP particle. Finally, rhodamine dye was conjugated to the surface amines of preloaded
the Gd44-G5-ss-Bt-pHLIP3 in order to achieve the final conjugate Rho-Gd44-G5-ss-BtpHLIP3 as shown in Figure 1. Unreacted dye was removed by diafiltration (using C-10).
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Free Gd3+ ions are toxic in vivo. To minimize toxicity Gd3+ ions are chelated with
multidentate ligands to prevent tissue interaction and minimize toxic side effects. However,
toxic Gd3+ ions may still be released in vivo by acid, competing endogenous metal ions such
as zinc, calcium and copper or metabolism of the chelates. This report employed only
macrocyclic chelates to tightly bind Gd3+.33 Macrocyclic chelates have significantly higher
thermodynamic stability constants than linear chelates. Gd-DOTA-4AmP5- is also kinetically
more stable than that of acyclic Gd-DTPA.34,35
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The exterior surface charge of this particle was assessed by zeta potential measurement. The
surface charges of Gd44-G5-Bt-pHLIP3 at pH 7.4 and 6.5 were −34.21 ± 2.99 mV and
− 2.41 ± 1.17 mV, respectively (Supplementary Figure S-1). This observation might be
explained by the presence of 44 Gd-DOTA-4AmP5– chelates on the surface of a G5
dendrimer. Gd-DOTA-4AmP5– chelate has variable pKa’s ranging from 6.0 to 8.0.35,34
Above the pKa’s, the chelate has −5 negative charge, while it has either neutral or positive
charge below the pKa’s.35 At acidic pH (<7.0), one or two aspartic residues in pHLIP
become protonated. However, at neutral pH, both aspartic acid residues are at deprotonated
state. Therefore, both Gd-DOTA-4AmP5– chelate and pHLIP played a significant role in
tuning the surface charge of the nanoparticle which is revealed by Zeta potential
measurements (Supplementary Figure S-1).
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To evaluate the ability of the peptide to translocate molecules across the cell membrane, we
synthesized a version of biotinylated pHLIP with a single cysteine residue at its C terminus
(AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG-(dpeg4Biotin) allowing it to be
easily conjugated to pyridinyldisulfide-activated Gd44-G5 through a sulphur-sulphur bond.
To study pH- dependent translocation of molecules across the cell membrane, we added
Rho-Gd44-G5-ss-Bt-pHLIP to the cells and incubated them for 3h at a pH of either 7.4 or
6.5. The cells were then washed at pH 7.4 to remove any reversibly bound peptide. RhoGd44-G5-ss-Bt-pHLIP did not exhibit any non-specific cellular up-take (Figure 2B), which
might be attributed to the repulsive inter-action between the negatively charged cell
membrane and negatively charged phosphonate-based Rho-Gd44-G5-ss-Bt-pHLIP
nanoparticles as evidenced by zeta potential measurement (Figure S-1).
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The cellular membrane insertion of Rho-Gd44-G5-pHLIP3 was also tested by an in vitro
MRI study at 7T using a Varian Direct- Drive MRI system (Figure 2E). Even incubation
with a higher dose (15 mM) of contrast agent did not cause cell distress or toxicity, in
agreement with previous reports.36 Therefore, the design of an anionic dendrimeric version
of MRI contrast agent aided in avoiding cell cytotoxicity. The cellular membrane binding of
the nanoparticle was observed only for pHLIP-conjugated Rho-Gd44-G5-ss-Bt-pHLIP at pH
6.5, as clearly demonstrated in Figure 2 (B, C, D) and 2E–F. Thus, we have shown the
ability of pHLIP peptide for intracellular delivery of Rho-Gd44-G5-ss-pHLIP3 in vitro at pH
6.5 but the same ability was attenuated significantly at neutral pH or pH 7.4. Fluorescent
microscopic imaging demonstrated the perinuclear fluorescence pattern (Figure 2F)
indicating endosomal localization of the nanoparticles. The images were captured in live
cells where we used LysoTracker to demonstrate co-localization of nanoparticles with
endosomes/lysosomes after 2 h of incubation, as shown in Figure 3. Therefore, at lower pH
(<7.0), Rho-Gd44-G5-ss-pHLIP3 was internalized into MDA-MB-231cells by the insertion
of pHLIP where sulphur-sulphur bond between Gd44-G5 and pHLIP in the nanostructure
was enzymatically cleaved upon trafficking into acidic endosomal or lysosomal subcellular
compartments, resulting in a release of Rho-Gd44-G5 nanoparticle into the cytoplasm
(Figure 2F). Several groups have also developed pHLIP-conjugated liposomes or polymers
for conditional delivery of drugs and demonstrated the feasibility of releasing drugs inside
endosomes/lysosomes.37,38
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Cellular entry of Rho-Gd44-G5-ss-Bt-pHLIP3 was also evaluated by flow cytometry.
Mesenchymal stem cells were used as a control (normal) cells. When these cells were
incubated with Rho-Gd44-G5-ss-Bt-pHLIP3 flow cytometry did not show any fluorescence
shift under both, pH 6.5 and 7.4 (Figure 4a). At the same time, three cancer cell lines, U251,
MDA-MB-231 and U87, treated with the same nanoparticles exhibited a very low level of
fluorescence shift at pH 7.4, due to low level of membrane attachment (red line in Figure 4 b
to d). However, at pH 6.5, a new population of highly fluorescent cells was observed for all
three cancer cell lines (blue line in Figure 4 b to d). We conclude that this dendrimeric platform can aid in intracellular delivering of therapeutic molecules that do not enter cells on
their own.
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In conclusion, we have demonstrated pH-responsive dual-mode optical/MRI contrast agent.
pH-dependent cellular internalization of (Gd-DOTA-4AmP)44-G5-ss-Bt-pHLIP3 was
evaluated by both in vitro MRI and microscopic fluorescence imaging. Finally, the platform
can be applied in different aggressive acidic cancer types, and where no other prognostic
factor is a reliable biomarker for response.
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Figure 1.

Schematic view of Gd3+ chelated with 1,4,7,10-tetraaza-cyclododecane-1,4,7,10tetraaminophosphonate (DOTA-4AmP8-) in a Gd44-G5 PAMAM dendrimer with rhodamine
(Rho) and Bt-pHLIP conjugation. Gd44-G5 is linked with Bt-pHLIP through sulphur-sulphur
bond.
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Figure 2.
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In vitro fluorescence microscopy of MDA-MB-231 cells incubated for 3 hours in media
containing rhodamine B conjugated Gd44-G5-pHLIP3 dendrimer at pH 7.4 and at pH 6.5 at a
concentration of 7.1 µM with respect to rhodamine B. Nuclei were visualized with DAPI
(blue fluorescence). Cyto-skeleton was visualized by FITC CytoPainter F-Actin specific dye
(green fluorescence). Intracellular uptake was visualized by red fluorescence of Rhodamine
conjugated to the nanoparticle (see B). Scale bars = 100 µm. Panel A showing cells
incubated in media only. Images of cells incubated in the presence of media and nanoparticle
were captured using DAPI and Rh filters (B), FITC and Rh filters (C) and DAPI, FITC and
Rh filters (D). Cytoskeleton was visualized by FITC Cyto-Painter F-Actin specific dye.
Panel 2E: In-vitro NP specificity quantified by MRI. T1- maps of gel phantoms containing
MDA-MB-231 cells incubated with NP at pH 6.5 and 7.4. Panel 2F: Enlarged image of
perinuclear distribution of Rho-Gd44-G5-ss-pHLIP3 from overlaid images of dapi and
nanoparticle (B).
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In vitro fluorescence microscopy images of MDA-MB-231 live cell incubated for 2 hours in
media containing rhodamine B conjugated Gd-G5—ss-Bt-pHLIP3 dendrimer at pH 6.5.
Nano-particle is red (A) and lysotracker green, detecting endosomes and lysosomes is shown
in green (B). Overlay between (A) and (B) is represented in yellow (C). Overlaid images are
shown in the far left and far right panel.
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Figure 4.
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Flow cytometry of the cell entry dynamics of Rho-Gd44-G5-ss-Bt-pHLIP3 conjugate
(particle is attached to C-terminus of the peptide) in MSC (a) (mesenchymal stem cell),
U251 (b), MDA-MB-231 (c) and U87 (d) cell lines. The log of rhodamine adsorption
intensity (FL1-H on X axis is plotted against the number of cells (counts on y axis). No
cellular uptake of the nanoparticle in normal MSC (a) was observed for both pH (6.5 and
7.4). In contrast, the cellular uptake of the nanaoparticle in all three cancer cell lines (b, c &
d) is evident at lower pH 6.5. (black line) Control (no probe at pH 7.4); (red line)
nanoparticle at pH 7.4; (blue line) nanoparticle at pH 6.5.
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